Clinical Trials Logo

Clinical Trial Summary

This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.


Clinical Trial Description

Observational and biochemical studies have identified an interesting pathway in the pathophysiology of certain clinical-biological characteristics of COVID-19, linked to an excess of serotonin. We hypothesize that the antagonism of the action of serotonin could improve the clinical course of patients most severely affected by COVID-19. One such antagonist of serotonin with a long track record of safety and tolerability is cyproheptadine. Cyproheptadine acts as an antagonist of 5-hydroxytryptamine (5HT=serotonin) receptor subtype 2 as well as histamine-1 receptor. Many of the potent effects of serotonin on lung vascular tone, respiratory rate, and systemic vascular beds are mediated by 5-HT receptor subtype 2. Investigators will randomize approximately 200 participants, aged 18 and older, who have tested positive for COVID-19 and who will be hospitalized at Santa Cabrini Hospital in Montreal, Quebec, Canada, presenting a severe form of covid-pneumonia-19 requiring supplemental oxygen. Study eligibility of all participants will be assessed first. Once a participant is confirmed eligible and consented, they will participate in the study. Participants will be randomly assigned (1: 1) to either take cyproheptadine 8 mg by mouth three times a day for 5 days and receive standard care or receive standard care alone. The dose will be adjusted according to the glomerular filtration rate. On D1, D3, D5, D7 and D10 since randomization, participant's vital signs (including SpO2, respiratory rate, FiO2 or oxygen flow, heart rate, blood pressure and temperature), blood creatinine, bilirubin, CRP, LDH, Dimers and platelets the count will be evaluated. Any adverse event will be assessed daily and documented. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04820751
Study type Interventional
Source Ciusss de L'Est de l'Île de Montréal
Contact Philippe Rola, MD
Phone 514 252-6000
Email philippe.rola@gmail.com
Status Not yet recruiting
Phase Phase 3
Start date April 10, 2021
Completion date January 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT04554901 - The Effect of Cocoa on Platelet Function Profiles in Patients N/A
Completed NCT03621020 - Clinical Performance Evaluation of T-TAS 01 PL Chip
Completed NCT03667066 - clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
Recruiting NCT05588011 - Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass N/A
Completed NCT01454427 - Influence of Anesthesia Drugs on Impedance Aggregometry N/A
Completed NCT03188705 - CES1 Carriers in the PAPI Study Phase 4
Recruiting NCT03583229 - Coronary Artery Disease After Heart Transplantation N/A
Recruiting NCT05730114 - Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Completed NCT03182946 - Correcting Platelet Dysfunction After Traumatic Brain Injury
Completed NCT05033236 - Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)
Recruiting NCT04419948 - Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM N/A
Completed NCT04400760 - The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts. Phase 2/Phase 3
Completed NCT03458351 - RIPC and Platelet Activation on Platelet Activation During Cardiopulmonary Bypass N/A
Completed NCT02368730 - Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures N/A
Recruiting NCT06405516 - Platelet Function After Cardiac Surgery. N/A
Not yet recruiting NCT04876573 - Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19 Phase 2
Completed NCT04734028 - PTRG-DES Consortium
Completed NCT01382134 - Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction N/A
Completed NCT03028064 - Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
Completed NCT05237492 - The Influence of Tramadol on Platelet Function Phase 4